harmonybiosciences.com (HRMY) Quick Ratio

The success of Harmony Biosciences (HRMY) is based on Wakix prescription dynamics and the approval of new indications from the FDA. To diversify its assets, the company is actively acquiring startups and licenses, which is reflected in the market price chart, where the current figure is 3.42. High scaling potential is driven by the development of sleep disorder treatments, where minimal production costs for patented drugs generate significant profits.

This indicator measures the company's ability to settle current liabilities without relying on slow-moving inventories, focusing exclusively on cash and accounts receivable. For Harmony Biosciences (HRMY), whose model is based on the high scalability of patented drugs, the quick ratio demonstrates capital management efficiency following the completion of costly clinical trials and the transition to the profit generation stage.